Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 664

1.

Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images.

Fiz F, Dittmann H, Campi C, Weissinger M, Sahbai S, Reimold M, Stenzl A, Piana M, Sambuceti G, la Fougère C.

Cancers (Basel). 2019 Jun 21;11(6). pii: E869. doi: 10.3390/cancers11060869.

2.

Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA.

Morera DS, Lahorewala SS, Belew D, Ghosh S, Klaassen Z, Jordan AR, Wang J, Terris MK, Bollag RJ, Merseburger AS, Stenzl A, Soloway MS, Lokeshwar VB.

J Urol. 2019 May 21:101097JU0000000000000351. doi: 10.1097/JU.0000000000000351. [Epub ahead of print]

PMID:
31112107
3.

[Surgical reconstruction of the ureter].

Stühler V, Bedke J, Stenzl A.

Urologe A. 2019 Jun;58(6):651-657. doi: 10.1007/s00120-019-0944-z. Review. German.

PMID:
31098652
4.

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.

Walz S, Maas M, Stenzl A, Todenhöfer T.

World J Mens Health. 2019 May 2. doi: 10.5534/wjmh.190044. [Epub ahead of print] Review.

5.

Stress urinary incontinence and regenerative medicine: is injecting functional cells into the urethra feasible based on current knowledge and future prospects?

Aufderklamm S, Aicher WK, Amend B, Stenzl A.

Curr Opin Urol. 2019 Jul;29(4):394-399. doi: 10.1097/MOU.0000000000000624.

PMID:
31033573
6.

The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.

Renninger M, Fahmy O, Schubert T, Schmid MA, Hassan F, Stenzl A, Gakis G.

World J Urol. 2019 Apr 27. doi: 10.1007/s00345-019-02780-0. [Epub ahead of print]

PMID:
31030231
7.

[Active surveillance in prostate cancer].

Erne E, Kaufmann S, Nikolaou K, Stenzl A, Bedke J.

Urologe A. 2019 May;58(5):511-517. doi: 10.1007/s00120-019-0921-6. Review. German.

PMID:
31016332
8.

Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.

Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, Fend F, Kruck S, Scharpf M, Stenzl A, Bedke J, Rausch S.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1835-1843. doi: 10.1007/s00432-019-02914-2. Epub 2019 Apr 22.

PMID:
31006846
9.

Inmunotherapy in prostate cancer.

Anselmo da Costa I, Stenzl A, Bedke J.

Arch Esp Urol. 2019 Mar;72(2):211-222.

PMID:
30855023
10.

Intention to treat analysis of 68Ga-PSMA and 11C-choline PET/CT versus CT for prostate cancer recurrences after surgery.

Schwenck J, Olthof SC, Pfannenberg C, Reischl G, Wegener D, Marzec J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.

J Nucl Med. 2019 Mar 8. pii: jnumed.118.224543. doi: 10.2967/jnumed.118.224543. [Epub ahead of print]

PMID:
30850491
11.

Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device.

Costa IAD, Hennenlotter J, Todenhöfer T, Neumann E, Deininger S, Aufderklamm S, Bedke J, Stenzl A, Rausch S.

Clin Lab. 2019 Jan 1;65(1). doi: 10.7754/Clin.Lab.2018.180710.

PMID:
30775903
12.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.

N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.

PMID:
30763142
13.

NLRP3/IL1β inflammasome associated with the aging bladder triggers bladder dysfunction in female rats.

Chen L, He PL, Yang J, Yang YF, Wang K, Amend B, Stenzl A, Zhang YM, Wang ZL, Xing SS, Luo X.

Mol Med Rep. 2019 Apr;19(4):2960-2968. doi: 10.3892/mmr.2019.9919. Epub 2019 Jan 31.

14.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A.

World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25. Review.

PMID:
30684034
15.

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA.

Eur Urol. 2019 May;75(5):853-860. doi: 10.1016/j.eururo.2018.11.055. Epub 2018 Dec 12.

PMID:
30553612
16.

Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.

Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, De Cobelli O, Artibani W, Cimino S, Morgia G, Damiano R, Nikolaou K, Kröger N, Stenzl A, Bedke J, Kruck S.

Prostate Cancer Prostatic Dis. 2019 May;22(2):206-220. doi: 10.1038/s41391-018-0113-2. Epub 2018 Nov 28. Review.

PMID:
30487646
17.

Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.

Stühler V, Maas JM, Bochem J, da Costa IA, Todenhöfer T, Stenzl A, Bedke J.

World J Urol. 2018 Oct 29. doi: 10.1007/s00345-018-2538-6. [Epub ahead of print]

PMID:
30374610
18.

mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.

Rausch S, Schollenberger D, Hennenlotter J, Stühler V, Kruck S, Stenzl A, Bedke J.

J Cancer Res Clin Oncol. 2019 Jan;145(1):153-163. doi: 10.1007/s00432-018-2775-5. Epub 2018 Oct 27.

PMID:
30368665
19.

[Mode of action, new targets and potential biomarkers in modern immunotherapy].

Bedke J, Stühler V, Todenhöfer T, Stenzl A.

Urologe A. 2018 Nov;57(11):1301-1308. doi: 10.1007/s00120-018-0787-z. Review. German.

PMID:
30350128
20.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15.

PMID:
30337060

Supplemental Content

Loading ...
Support Center